Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists-Reference-Cited by-同舟云学术

Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists

Published:2018-04-10 Issue:2 Volume:11 Page:113-121
ISSN:1874-4672
Container-title:Current Molecular Pharmacology
language:en
Short-container-title:CMP

Author:

Zhao Yi¹,Wu Kaijin²,Wu Yongfeng¹,Melendez Elizabeth²,Smbatyan Goar²,Massiello David¹,Kahn Michael¹

Affiliation:

1. Center for Molecular Pathways and Drug Discovery, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States

2. Department of Biochemistry and Molecular Biology, Norris Comprehensive Cancer Research Center, Keck School of Medicine of University of Southern California, Los Angeles, California, CA, United States

Publisher

Bentham Science Publishers Ltd.

Subject

General Health Professions

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer Stem Cells from Definition to Detection and Targeted Drugs;International Journal of Molecular Sciences;2024-03-31

2. A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I;Current Molecular Pharmacology;2023-10-02

3. TXNRD1: A Key Regulator Involved in the Ferroptosis of CML Cells Induced by Cysteine Depletion In Vitro;Oxidative Medicine and Cellular Longevity;2021-12-07

4. Differential Kat3 Usage Orchestrates the Integration of Cellular Metabolism with Differentiation;Cancers;2021-11-23

5. Taking the road less traveled – the therapeutic potential of CBP/β-catenin antagonists;Expert Opinion on Therapeutic Targets;2021-09-02